Modality
Cell Therapy
MOA
CD3xCD20
Target
KRASG12C
Pathway
Apoptosis
RettHCC
Development Pipeline
Preclinical
Apr 2018
→ Jul 2031
PreclinicalCurrent
NCT06607755
2,538 pts·HCC
2018-04→2031-07·Recruiting
NCT07329646
994 pts·Rett
2025-09→2029-03·Active
3,532 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-03-072.9y awayInterim· Rett
2031-07-195.3y awayInterim· HCC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Recruit…
Preclinical
Active
Catalysts
Interim
2029-03-07 · 2.9y away
Rett
Interim
2031-07-19 · 5.3y away
HCC
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06607755 | Preclinical | HCC | Recruiting | 2538 | 6MWD |
| NCT07329646 | Preclinical | Rett | Active | 994 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C |